Glutamate Reducing Interventions in Schizophrenia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Participants will be administered several doses of pomaglumetad (POMA) (low and high doses) over 14 days to individuals at clinical high risk for developing psychosis and use magnetic resonance imaging (MRI) brain imaging to determine whether these doses of POMA are affecting glutamate levels.
Epistemonikos ID: 0e47c1a7a78850f6b4dd5f688a9e401350103ecd
First added on: May 21, 2024